Feed ACRS
AC

Aclaris Therapeutics, Inc.

ACRS · NASDAQ

$5.26 -0.94% (-$0.05)
1M -12.62%
Market Cap $734.6M
P/E Ratio -
Div. Yield -
ROE 61.65%
Analiza

AI poročilo o poslu, financah, vrednotenju, razpoloženju, novicah in tveganjih - napisano v nekaj minutah.

Piotroski F-Score Weak
2/9
Valuation
13 /100
Expensive
P/B 5.90x
P/S 89.38x
PEG N/A
Growth
0 /100
Declining
Book val. growth 19.50%
Rev. growth 35.93%
FCF growth N/A
Profitability
20 /100
Weak
FCF margin 756.50%
Op. margin 1,050.16%
Gross margin 95.61%
Quality
1 /100
Poor
Asset turnover 0.05x
ROA 42.15%
ROIC 61.59%
Debt
100 /100
Low
Current ratio 3.46x
Debt/Equity 0.00x
Net debt/EBITDA N/A
Stability
43 /100
Moderate
Profitable years 0
EPS volatility 52.34%
Beta 0.80x

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o ACRS
Online

O podjetju

Aclaris Therapeutics, Inc. (ACRS) is a biotechnology company focused on researching, developing, and commercializing therapeutics for dermatological conditions and skin-related health issues. The company concentrates on innovative therapeutic approaches and medicinal products that target various dermatological indications, including skin disorders and autoimmune conditions. Aclaris Therapeutics, Inc. has a strong research foundation and collaborates with skin experts and dermatologists to develop effective treatment methods. With its innovations and focus on skin health, investing in Aclaris Therapeutics, Inc. (ACRS) shares may present an interesting investment opportunity for investors interested in the biotechnology and medical sectors.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Neal S. Walker

Employees

71

Headquarters

Wayne

Prihajajoči dogodki

05 NOV.

Earnings

Upcoming earnings report

35d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.